SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (266)5/21/1999 4:43:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1475
 
Peter:

Thanks, what a nice summary. This study was reported late last year and caused the stock to jump from $1 63/64 to $2 on 300 shares. Surprised you don't remember.

- g -

Thanks! Rick




To: Biomaven who wrote (266)5/26/1999 1:50:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1475
 
the version for popular digestion......

biz.yahoo.com

Recent studies published..... (1) graft-versus-lymphoma with long-term remission in two of four evaluable/terminal patients, and (2) liver transplantation using the murine precursor for 507.

Studies to be described soon.... MEDI and phase II, 507 for GvH.

Market capitalization....... 29 million.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News